Opioid Induced Constipation News and Research

RSS
Top-line data from S.L.A. Pharma’s Nalcol Phase 2 study on OIC

Top-line data from S.L.A. Pharma’s Nalcol Phase 2 study on OIC

Salix first quarter total product revenue increases 62% to $171.1M

Salix first quarter total product revenue increases 62% to $171.1M

Methylnaltrexone may restore bowel function in critically ill patients

Methylnaltrexone may restore bowel function in critically ill patients

Salix third quarter total product revenue increases 81% to $146.2 million

Salix third quarter total product revenue increases 81% to $146.2 million

Cubist signs definitive agreement to acquire Adolor

Cubist signs definitive agreement to acquire Adolor

Alkermes initiates ALKS 37 phase 2b study in opioid-induced constipation

Alkermes initiates ALKS 37 phase 2b study in opioid-induced constipation

FDA accepts Salix and Progenics' sNDA filing for RELISTOR to treat opioid-induced constipation

FDA accepts Salix and Progenics' sNDA filing for RELISTOR to treat opioid-induced constipation

Positive results from two ADL5945 Phase 2 studies for opioid-induced constipation

Positive results from two ADL5945 Phase 2 studies for opioid-induced constipation

AstraZeneca recruits patients for KODIAC Phase III trial in opioid-induced constipation

AstraZeneca recruits patients for KODIAC Phase III trial in opioid-induced constipation

Enrollment complete in Adolor's ADL5945 Phase 2 clinical study in opioid-induced constipation

Enrollment complete in Adolor's ADL5945 Phase 2 clinical study in opioid-induced constipation

Phase 3 open-label study of RELISTOR presented at American Pain Society meeting

Phase 3 open-label study of RELISTOR presented at American Pain Society meeting

AstraZeneca commences NKTR-118 Phase III clinical programme for opioid-induced constipation

AstraZeneca commences NKTR-118 Phase III clinical programme for opioid-induced constipation

Progenics, Salix enter exclusive worldwide license agreement for RELISTOR

Progenics, Salix enter exclusive worldwide license agreement for RELISTOR

Adolor initiates second ADL5945 Phase 2 study in opioid-induced constipation

Adolor initiates second ADL5945 Phase 2 study in opioid-induced constipation

Progenics initiates ONO-3849 phase 2 clinical trial for OIC in Japan

Progenics initiates ONO-3849 phase 2 clinical trial for OIC in Japan

Progenics third quarter net loss increases to $17.1 million

Progenics third quarter net loss increases to $17.1 million

Adolor initiates ADL5945 Phase 2 proof-of-concept study for patients with OIC

Adolor initiates ADL5945 Phase 2 proof-of-concept study for patients with OIC

FDA, EMA and Health Canada approve Progenics' RELISTOR in pre-filled syringes

FDA, EMA and Health Canada approve Progenics' RELISTOR in pre-filled syringes

Progenics completes methylnaltrexone bromide subcutaneous injection phase 3 study in patients with OIC

Progenics completes methylnaltrexone bromide subcutaneous injection phase 3 study in patients with OIC

Progenics commences Phase 3 trial of oral methylnaltrexone for opioid-induced constipation

Progenics commences Phase 3 trial of oral methylnaltrexone for opioid-induced constipation